Ponesimod Drug Asset Due Diligence Report 2026

This Ponesimod Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Approved

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: GO

Decision memo

Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.

The central underwriting question is whether Ponesimod can convert its Small molecule drug profile and S1PR1 biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Ponesimod (query alias: ponesimod)
Modality / target	Small molecule drug; S1PR1; S1PR1 modulators
Highest global status	Approved
Originator	Actelion Pharmaceuticals Ltd.
Active developers	Vanda Pharmaceuticals, Inc., Laboratoires Juvise Pharmaceuticals SASU, Janssen, Inc.

The MCP disease footprint includes Multiple sclerosis relapse, Colitis, Ulcerative, Plaque psoriasis. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT07362017	Phase 3	Recruiting	300	Safety and tolerability of ponesimod as measured by reporting of adverse events (AEs)
EUCTR2020-004431-24-3RD	Phase 3		212	Time from randomization to first confirmed relapse
NCT07686081	Phase 3	Not yet recruiting	150	Clinical Remission at Week 16

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

Ponesimod as add-on treatment in patients with active relapsing multiple sclerosis under dimethyl fumarate (POINT): A phase 3, randomized, placebo-controlled clinical trial

Phase 3; n=136; evaluation: Negative. Reported fields: ARR: RR = 1.2, P-Value = 0.5252; ARR: RR = 1.2, P-Value = 0.5252

Multicenter, Non-comparative Extension of Study AC-058B301, to Investigate the Long-term Safety, Tolerability, and Control of Disease of Ponesimod 20 mg in Subjects With Relapsing Multiple Sclerosis

Phase 3; n=877; evaluation: not stated. Reported fields: Annualized Confirmed Relapse Rate (ARR)(Mean) = 0.184 relapses per patient-year (95% Confidence Interval, 0.158 - 0.213); Annualized Confirmed Relapse Rate (ARR)(Mean) = 0.143 relapses per patient-year (95% Confidence Interval, 0.123 - 0.167); Annualized Confirmed Relapse Rate (ARR)(Mean): Treatment Effect (Rate Ratio) = 0.779(95% CI, 0.629 - 0.965)

Multicenter, Randomized, Double-blind, Parallel-group Extension to Study AC-058B201 to Investigate the Long-term Safety, Tolerability, and Efficacy of Three Doses of Ponesimod, an Oral S1P1 Receptor Agonist, in Patients With Relapsing-remitting Multiple Sclerosis

Phase 2; n=353; evaluation: not stated. Reported fields: Annualized Relapse Rate (ARR) of Confirmed Relapses(Mean) = 0.150 Confirmed relapses per year (95% Confidence Interval, 0.105 - 0.215); Annualized Relapse Rate (ARR) of Confirmed Relapses(Mean) = 0.205 Confirmed relapses per year (95% Confidence Interval, 0.150 - 0.282); -

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Ponesimod addresses Multiple sclerosis relapse, Colitis, Ulcerative, Plaque psoriasis. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 2 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2024-03-26	Juvisé Pharmaceuticals Acquires Multiple Sclerosis Drug PONVORY® (ex-US/Canada) and Opens Its Capital to Bpifrance and Pemberton	Approved	Financial terms not disclosed
2023-12-07	Vanda Pharmaceuticals Acquires U.S. and Canadian Rights to PONVORY® (ponesimod), a Selective S1P1R Modulator Approved for Patients with Relapsing Multiple Sclerosis	Not disclosed	US$100.0M stated total

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Process for the preparation of ponesimod”. The milestone feed surfaced a patent-application signal described as “Process for the preparation of ponesimod and its intermediates thereof”. The milestone feed surfaced a patent-application signal described as “Polymorphs of ponesimod”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Therapeutic index across KRAS/BRAF mutation subgroups
On-target toxicity and adaptive MAPK resistance
Lack of matched efficacy results in the current MCP result set

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

GO